Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Ijlh 44 101
Ijlh 44 101
Natalia Henao-Piedrahita1
1
Médica General, Fundación Universitaria San Martín. Sabaneta, Colombia. E-mail: natalia.henao.pi@gmail.com.
explicar de forma clara y precisa aspec- rara vez este hallazgo se hace clínica-
tos generales como la fisiopatología, mente evidente [9]. La autopsia de
manifestaciones clínicas, diagnóstico y los pacientes con MAT generalmente
tratamiento de las tres microangiopa- muestra trombos microvasculares en la
tías trombóticas primarias. mayoría de órganos [5]. Algunas enfer-
medades que pueden tener caracterís-
ticas similares a las MAT se enuncian en
Generalidades la tabla 1.
VIH: virus de inmunodeficiencia primaria; HHV-6: herpesvirus humano 6; EBV: virus de Epstein-Bar.
Realizar pruebas para ADAMTS13 y toxina Shiga Descartar causas secundarias asociadas a MAT
No respuesta al tratamiento
dren and adults with thrombotic thrombocyto- cleaving protease in thrombotic thrombocyto-
penic purpura associated with severe, acquired penic purpura and the hemolytic-uremic syndro-
Adamts13 deficiency: comparison of inciden- me. N Engl J Med 1998;339:1578-1584. https://
ce, demographic and clinical features. Pediatr doi.org/10.1056/nejm199811263392202.
Blood Cancer 2013;60:1676-1682. https://doi. 25. Blombery P, Scully M. Management of throm-
org/10.1002/pbc.24612. botic thrombocytopenic purpura: current pers-
17. Terrell DR, Williams LA, Vesely SK, Lämmle B, pectives. J Blood Med 2014;5:15-23. https://
Hovinga JA, George JN. The incidence of throm- doi.org/10.2147/jbm.S46458.
botic thrombocytopenic purpura-hemolytic ure- 26. Kappler S, Ronan-Bentle S, Graham A.
mic syndrome: all patients, idiopathic patients, Thrombotic microangiopathies (TTP, HUS,
and patients with severe ADAMTS-13 deficiency. HELLP). Hematol Oncol Clin North Am
J Thromb Haemost 2005;3:1432-1436. https:// 2017;31:1081-1103. https://doi.org/10.1016/j.
doi.org/10.1111/j.1538-7836.2005.01436.x. hoc.2017.08.010.
18. Terrell DR, Vesely SK, Kremer Hovinga JA, 27. Griffin D, Al-Nouri ZL, Muthurajah D, Ross JR,
Lämmle B, George JN. Different disparities of Ballard RB, Terrell DR, et al. First symptoms
gender and race among the thrombotic throm- in patients with thrombotic thrombocytopenic
bocytopenic purpura and hemolytic-uremic purpura: what are they and when do they oc-
syndromes. Am J Hematol 2010;85:844-847. cur? Transfusion 2013;53:235-237. https://doi.
https://doi.org/10.1002/ajh.21833. org/10.1111/j.1537-2995.2012.03934.x.
19. Moake JL, Rudy CK, Troll JH, Weinstein MJ, 28. George JN. How I treat patients with throm-
Colannino NM, Azocar J, et al. Unusually botic thrombocytopenic purpura: 2010. Blood
large plasma factor VIII:von Willebrand fac- 2010;116:4060-4069. https://doi.org/10.1182/
tor multimers in chronic relapsing thrombo- blood-2010-07-271445.
tic thrombocytopenic purpura. N Engl J Med 29. Vesely SK, George JN, Lämmle B, Studt
1982;307:1432-1435. https://doi.org/10.1056/ JD, Alberio L, El-Harake MA, et al. ADA-
nejm198212023072306. MTS13 activity in thrombotic thrombocyto-
20. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, penic purpura-hemolytic uremic syndrome:
Kaketani K. Immunohistochemistry of vascular relation to presenting features and clinical
lesion in thrombotic thrombocytopenic purpu- outcomes in a prospective cohort of 142
ra, with special reference to factor VIII related patients. Blood 2003;102:60-68. https://doi.
antigen. Thromb Res 1985;38:469-479. https:// org/10.1182/blood-2003-01-0193.
doi.org/10.1016/0049-3848(85)90180-x. 30. Brocklebank V, Wood KM, Kavanagh D.
21. Vacca VM, Jr. Acquired autoimmune throm- Thrombotic microangiopathy and the kid-
botic thrombocytopenic purpura. Nursing ney. Clin J Am Soc Nephrol 2018;13:300-317.
2019;49:22-29. https://doi.org/10.1097/01. https://doi.org/10.2215/cjn.00620117.
NURSE.0000549721.69197.4d. 31. Bendapudi PK, Hurwitz S, Fry A, Marques
22. Moake JL, Turner NA, Stathopoulos NA, No- MB, Waldo SW, Li A, et al. Derivation and ex-
lasco LH, Hellums JD. Involvement of large ternal validation of the PLASMIC score for rapid
plasma von Willebrand factor (vWF) multimers assessment of adults with thrombotic microan-
and unusually large vWF forms derived from giopathies: a cohort study. Lancet Haematol
endothelial cells in shear stress-induced pla- 2017;4:e157-e164. https://doi.org/10.1016/
telet aggregation. J Clin Invest 1986;78:1456- s2352-3026(17)30026-1.
1461. https://doi.org/10.1172/jci112736. 32. George JN. Systemic malignancies as a cau-
23. Zander CB, Cao W, Zheng XL. ADAMTS13 se of unexpected microangiopathic hemolytic
and von Willebrand factor interactions. Curr anemia and thrombocytopenia. Oncology
Opin Hematol 2015;22:452-459. https://doi. 2011;25:908-914.
org/10.1097/moh.0000000000000169. 33. Furlan M, Robles R, Morselli B, Sandoz P,
24. Furlan M, Robles R, Galbusera M, Remuzzi G, Lämmle B. Recovery and half-life of von Wille-
Kyrle PA, Brenner B, et al. von Willebrand factor- brand factor-cleaving protease after plasma the-
rapy in patients with thrombotic thrombocyto- 42. Witham PK, Yamashiro CT, Livak KJ, Batt
penic purpura. Thromb Haemost 1999;81:8-13. CA. A PCR-based assay for the detection of Es-
34. Zheng XL, Vesely SK, Cataland SR, Coppo cherichia coli Shiga-like toxin genes in ground
P, Geldziler B, Iorio A, et al. ISTH guidelines beef. Appl Environ Microbiol 1996;62:1347-
for treatment of thrombotic thrombocytopenic 1353. https://doi.org/10.1128/aem.62.4.1347-
purpura. J Thromb Haemost 2020;18:2496- 1353.1996.
2502. https://doi.org/10.1111/jth.15010. 43. Bell BP, Goldoft M, Griffin PM, Davis MA,
35. Scully M, Hunt BJ, Benjamin S, Liesner R, Gordon DC, Tarr PI, et al. A multistate out-
Rose P, Peyvandi F, et al. Guidelines on the break of Escherichia coli O157:H7-associated
diagnosis and management of thrombotic bloody diarrhea and hemolytic uremic syndro-
thrombocytopenic purpura and other throm- me from hamburgers. The Washington expe-
botic microangiopathies. Br J Haematol rience. Jama 1994;272:1349-1353.
2012;158:323-335. https://doi.org/10.1111/ 44. Buchholz U, Bernard H, Werber D, Böhmer
j.1365-2141.2012.09167.x. MM, Remschmidt C, Wilking H, et al. Ger-
36. Schwartz J, Padmanabhan A, Aqui N, Balo- man outbreak of Escherichia coli O104:H4
gun RA, Connelly-Smith L, Delaney M, et al. associated with sprouts. N Engl J Med
Guidelines on the use of therapeutic apheresis 2011;365:1763-1770. https://doi.org/10.1056/
in clinical practice-evidence-based approach NEJMoa1106482.
from the Writing Committee of the American 45. Noris M, Remuzzi G. Hemolytic uremic syn-
Society for Apheresis: The seventh special is- drome. J Am Soc Nephrol 2005;16:1035-1050.
sue. J Clin Apher 2016;31:149-162. https://doi. https://doi.org/10.1681/asn.2004100861.
org/10.1002/jca.21470. 46. Cody EM, Dixon BP. Hemolytic uremic syndro-
37. Scully M, Cataland S, Coppo P, de la Rubia me. Pediatr Clin North Am 2019;66:235-246.
J, Friedman KD, Kremer Hovinga J, et al. https://doi.org/10.1016/j.pcl.2018.09.011.
Consensus on the standardization of termino- 47. Karpac CA, Li X, Terrell DR, Kremer Hovinga
logy in thrombotic thrombocytopenic purpura JA, Lämmle B, Vesely SK, et al. Sporadic bloo-
and related thrombotic microangiopathies. J dy diarrhoea-associated thrombotic thrombo-
Thromb Haemost 2017;15:312-322. https:// cytopenic purpura-haemolytic uraemic syn-
doi.org/10.1111/jth.13571. drome: an adult and paediatric comparison.
38. Wang HX, Han B, Zhao YY, Kou L, Guo LL, Br J Haematol 2008;141:696-707. https://doi.
Sun TW, et al. Serum D-dimer as a potential org/10.1111/j.1365-2141.2008.07116.x.
new biomarker for prognosis in patients with 48. Manrique-Caballero CL, Peerapornratana
thrombotic thrombocytopenic purpura. Medi- S, Formeck C, Del Rio-Pertuz G, Gomez Da-
cine (Baltimore) 2020;99:e19563. https://doi. nies H, Kellum JA. Typical and atypical he-
org/10.1097/md.0000000000019563. molytic uremic syndrome in the critically ill.
39. Gasser C, Gautier E, Steck A, Siebenmann Crit Care Clin 2020;36:333-356. https://doi.
RE, Oechslin R. [Hemolytic-uremic syndrome: org/10.1016/j.ccc.2019.11.004.
bilateral necrosis of the renal cortex in acute 49. Spinale JM, Ruebner RL, Copelovitch L, Ka-
acquired hemolytic anemia]. Schweiz Med Wo- plan BS. Long-term outcomes of Shiga toxin
chenschr 1955;85:905-909. hemolytic uremic syndrome. Pediatr Nephrol
40. Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loi- 2013;28:2097-2105. https://doi.org/10.1007/
rat C. Haemolytic uraemic syndrome. Lancet s00467-012-2383-6.
2017;390:681-696. https://doi.org/10.1016/s0140- 50. Garg AX, Suri RS, Barrowman N, Rehman F,
6736(17)30062-4. Matsell D, Rosas-Arellano MP, et al. Long-
41. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin- term renal prognosis of diarrhea-associated
producing Escherichia coli and haemolytic urae- hemolytic uremic syndrome: a systematic re-
mic syndrome. Lancet 2005;365:1073-1086. view, meta-analysis, and meta-regression. Jama
https://doi.org/10.1016/s0140-6736(05)71144- 2003;290:1360-1370. https://doi.org/10.1001/
2. jama.290.10.1360.
51. Taylor CM, Machin S, Wigmore SJ, Good- G, et al. Differential impact of complement
ship TH. Clinical practice guidelines for the mutations on clinical characteristics in atypical
management of atypical haemolytic uraemic hemolytic uremic syndrome. J Am Soc Nephrol
syndrome in the United Kingdom. Br J Haema- 2007;18:2392-2400. https://doi.org/10.1681/
tol 2010;148:37-47. https://doi.org/10.1111/ asn.2006080811.
j.1365-2141.2009.07916.x. 58. Goodship TH, Cook HT, Fakhouri F, Fervenza
52. Geerdink LM, Westra D, van Wijk JA, Dorres- FC, Frémeaux-Bacchi V, Kavanagh D, et al. Aty-
teijn EM, Lilien MR, Davin JC, et al. Atypical pical hemolytic uremic syndrome and C3 glome-
hemolytic uremic syndrome in children: com- rulopathy: conclusions from a "Kidney disease:
plement mutations and clinical characteristics. Improving global outcomes" (KDIGO) Contro-
Pediatr Nephrol 2012;27:1283-1291. https:// versies Conference. Kidney Int 2017;91:539-551.
doi.org/10.1007/s00467-012-2131-y. https://doi.org/10.1016/j.kint.2016.10.005.
53. Hofer J, Janecke AR, Zimmerhackl LB, Riedl 59. Cataland SR, Holers VM, Geyer S, Yang
M, Rosales A, Giner T, et al. Complement S, Wu HM. Biomarkers of terminal comple-
factor H-related protein 1 deficiency and fac- ment activation confirm the diagnosis of
tor H antibodies in pediatric patients with aHUS and differentiate aHUS from TTP. Blood
atypical hemolytic uremic syndrome. Clin J 2014;123:3733-3738. https://doi.org/10.1182/
Am Soc Nephrol 2013;8:407-415. https://doi. blood-2013-12-547067.
org/10.2215/cjn.01260212. 60. Noris M, Remuzzi G. Atypical hemolytic-uremic
54. Licht C, Ardissino G, Ariceta G, Cohen D, Cole syndrome. N Engl J Med 2009;361:1676-1687.
JA, Gasteyger C, et al. The global aHUS regis- https://doi.org/10.1056/NEJMra0902814.
try: methodology and initial patient characte- 61. Masias C, Vasu S, Cataland SR. None of the abo-
ristics. BMC Nephrol 2015;16:207. https://doi. ve: thrombotic microangiopathy beyond TTP
org/10.1186/s12882-015-0195-1. and HUS. Blood 2017;129:2857-2863. https://
55. Makou E, Herbert AP, Barlow PN. Functional doi.org/10.1182/blood-2016-11-743104.
anatomy of complement factor H. Biochemistry 62. Gordon CE, Chitalia VC, Sloan JM, Salant
2013;52:3949-3962. https://doi.org/10.1021/ DJ, Coleman DL, Quillen K, et al. Thrombo-
bi4003452. tic microangiopathy: A multidisciplinary team
56. Noris M, Caprioli J, Bresin E, Mossali C, Pia- approach. Am J Kidney Dis 2017;70:715-721.
netti G, Gamba S, et al. Relative role of gene- https://doi.org/10.1053/j.ajkd.2017.05.017.
tic complement abnormalities in sporadic and 63. Bittencourt CE, Ha JP, Maitta RW. Re-exami-
familial aHUS and their impact on clinical phe- nation of 30-day survival and relapse rates in
notype. Clin J Am Soc Nephrol 2010;5:1844- patients with thrombotic thrombocytopenic
1859. https://doi.org/10.2215/cjn.02210310. purpura-hemolytic uremic syndrome. PLoS One
57. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dra- 2015;10:e0127744. https://doi.org/10.1371/jour-
gon-Durey MA, Macher MA, Niaudet P, Guest nal.pone.0127744.